Navigation Links
ADVENTRX Announces Consolidation of Clinical and Management Positions
Date:1/30/2008

SAN DIEGO, Jan. 30 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced today that Evan M. Levine, the company's current Chief Executive Officer, has resumed his position as Chief Executive Officer and President, a position he held from September 2004 through September 2006.

The company also announced that James A. Merritt's employment relationship with the company ended, effective January 29, 2008. Dr. Merritt previously served as the company's President and Chief Medical Officer. In connection with these events, the underlying responsibilities of the Chief Medical Officer and President positions have been consolidated. Joachim P.H. Schupp, M.D., who has served as the company's Vice President, Medical Affairs since August 2006, will lead the company's clinical group and assume Dr. Merritt's clinical responsibilities, and Mr. Levine will resume the corporate responsibilities of the President.

"We have an experienced team that will continue to rapidly advance our lead programs and we are excited by our continued progress and anticipate achieving additional milestones in 2008," stated Mr. Levine. "On behalf of our board of directors and the entire management team, we thank Jay for his contributions to the company and wish him well," added Mr. Levine.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals seeks to improve the performance and safety of existing treatments by addressing significant problems such as drug metabolism, bioavailability, excessive toxicity and treatment resistance. More information can be found on the Company's web site at http://www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors that, if they do not materialize or prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that preclinical and clinical results are not indicative of the success of subsequent clinical trials and that products will not perform as preclinical or clinical data suggests or as otherwise anticipated; the results of pending clinical trials for ADVENTRX's product candidates; the FDA's views on the appropriateness of seeking marketing approval of certain of ADVENTRX's product candidates under Section 505(b)(2); difficulties or delays in developing, testing, manufacturing and marketing and obtaining regulatory approval for ADVENTRX's product candidates, including receiving necessary regulatory approvals for clinical trials of ANX-514; the potential for regulatory authorities to require additional preclinical work or other clinical requirements to support regulatory filings; patent and non-patent exclusivity covering ADVENTRX's Section 505(b)(2) product candidates; the risk that ADVENTRX will be unable to raise sufficient capital to fund the projects necessary to meet its anticipated or stated goals and milestones; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date on which it was made.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
4. ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
5. ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference
6. ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
7. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
8. ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum
9. ADVENTRX Appoints Vice President of Commercialization
10. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... , May 23, 2016 - Leading CRO,s ... - Frontage Implement a Single Platform to Manage End-to-end ... Traceability Within the Bioanalytical lab Frontage Laboratories, a full-service ... States and China , has selected ... facilities. In addition to serving as the global electronic lab notebook ...
(Date:5/20/2016)... San Diego, CA (PRWEB) , ... May 20, 2016 , ... ... announce that 10 of its most experienced veterinary clients have treated over 100 of ... this cutting edge technology to provide the highest level of care for their patients. ...
(Date:5/19/2016)... ... May 19, 2016 , ... Anton Paar USA, located ... foot office building is complete. The new structure adds a third office building to ... Paar USA purchased 2.4 acres of land, along with office space adjacent to ...
(Date:5/19/2016)... SAN DIEGO , May 19, 2016 /PRNewswire/ ... (OTCBB: RGBP), (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced ... at creating the first cord blood based cancer ... a provisional patent application, Regen described a generation ... activity was potentiated by gene silencing.  The product ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
Breaking Biology News(10 mins):